NanoViricides Inc
NNVC1.610USD
+0.030+1.89%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
25.87MCap. mercado
PérdidaP/E TTM
Más Datos de NanoViricides Inc Compañía
NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
Información de la empresa
Símbolo de cotizaciónNNVC
Nombre de la empresaNanoViricides Inc
Fecha de salida a bolsaAug 12, 2004
Director ejecutivoDr. Anil Diwan, Ph.D.
Número de empleados7
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 12
Dirección1 Controls Drive
CiudadSHELTON
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal06484
Teléfono12039376137
Sitio Webhttps://www.nanoviricides.com/
Símbolo de cotizaciónNNVC
Fecha de salida a bolsaAug 12, 2004
Director ejecutivoDr. Anil Diwan, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Meeta Vyas
Meeta Vyas
Chief Financial Officer
Chief Financial Officer
7.13K
--
Dr. Anil Diwan, Ph.D.
Dr. Anil Diwan, Ph.D.
President, Chief Executive Officer, Executive Chairman of the Board
President, Chief Executive Officer, Executive Chairman of the Board
--
--
Dr. Makarand (Mak) Jawadekar, Ph.D.
Dr. Makarand (Mak) Jawadekar, Ph.D.
Independent Director
Independent Director
--
--
Mr. Theodore Edward (Todd) Rokita, J.D.
Mr. Theodore Edward (Todd) Rokita, J.D.
Independent Director
Independent Director
--
--
Mr. Brian F. Zucker
Mr. Brian F. Zucker
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Meeta Vyas
Meeta Vyas
Chief Financial Officer
Chief Financial Officer
7.13K
--
Dr. Anil Diwan, Ph.D.
Dr. Anil Diwan, Ph.D.
President, Chief Executive Officer, Executive Chairman of the Board
President, Chief Executive Officer, Executive Chairman of the Board
--
--
Dr. Makarand (Mak) Jawadekar, Ph.D.
Dr. Makarand (Mak) Jawadekar, Ph.D.
Independent Director
Independent Director
--
--
Mr. Theodore Edward (Todd) Rokita, J.D.
Mr. Theodore Edward (Todd) Rokita, J.D.
Independent Director
Independent Director
--
--
Mr. Brian F. Zucker
Mr. Brian F. Zucker
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 16 de jul
Actualizado: mié., 16 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
3.18%
Theracour Pharma, Inc.
2.93%
BlackRock Institutional Trust Company, N.A.
0.99%
Geode Capital Management, L.L.C.
0.96%
Renaissance Technologies LLC
0.66%
Other
91.29%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
3.18%
Theracour Pharma, Inc.
2.93%
BlackRock Institutional Trust Company, N.A.
0.99%
Geode Capital Management, L.L.C.
0.96%
Renaissance Technologies LLC
0.66%
Other
91.29%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
4.91%
Corporation
2.93%
Investment Advisor/Hedge Fund
1.70%
Hedge Fund
0.69%
Individual Investor
0.60%
Venture Capital
0.32%
Research Firm
0.23%
Bank and Trust
0.03%
Other
88.60%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
61
1.83M
11.40%
-362.26K
2025Q1
63
2.05M
12.78%
-124.35K
2024Q4
61
2.03M
12.98%
-23.52K
2024Q3
60
1.91M
13.93%
-126.25K
2024Q2
62
1.91M
16.17%
+50.13K
2024Q1
62
1.74M
14.78%
-267.11K
2023Q4
64
1.76M
14.98%
-214.22K
2023Q3
67
1.72M
14.71%
-264.52K
2023Q2
63
1.75M
15.01%
-221.57K
2023Q1
69
1.77M
15.19%
-341.23K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
510.42K
3.18%
--
--
Mar 31, 2025
Theracour Pharma, Inc.
470.96K
2.93%
--
--
Oct 09, 2024
BlackRock Institutional Trust Company, N.A.
158.75K
0.99%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
154.59K
0.96%
+11.28K
+7.87%
Mar 31, 2025
Renaissance Technologies LLC
105.80K
0.66%
-39.90K
-27.39%
Mar 31, 2025
XTX Markets LLC
51.25K
0.32%
+51.25K
--
Mar 31, 2025
Bridgeway Capital Management, LLC
44.04K
0.27%
--
--
Mar 31, 2025
State Street Global Advisors (US)
41.91K
0.26%
--
--
Mar 31, 2025
City National Rochdale, LLC
30.54K
0.19%
--
--
Mar 31, 2025
Jawadakar (Makarand)
30.50K
0.19%
--
--
Oct 09, 2024
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
